{"id":"al8326-low-dose-group","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-15%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL2108795","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, AL8326 reduces glucose reabsorption in the kidneys, lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes. AL8326's effects on blood glucose levels are dose-dependent and may vary across different patient populations.","oneSentence":"AL8326 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:20:33.160Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT05363280","phase":"PHASE2","title":"Phase 2 Safety and Efficacy Evaluation of AL8326 in ≥2nd Line SCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Advenchen Pharmaceuticals, LLC.","startDate":"2022-11-01","conditions":"Small Cell Lung Cancer","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3516,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AL8326 low dose group","genericName":"AL8326 low dose group","companyName":"Advenchen Pharmaceuticals, LLC.","companyId":"advenchen-pharmaceuticals-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AL8326 is being studied in a Phase 2 clinical trial for the treatment of Small Cell Lung Cancer, Non-Small Cell Lung Cancer, and Renal Cell Carcinoma. The low dose group of AL8326 in this trial is not specified, as the doses studied are 40 mg, 60 mg, and 80 mg.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}